LOS ANGELES, CA -- (Marketwired) -- 04/22/13 -- In a newly published Expert Briefing which appears at BioMedReports, David Platt, Ph.D., CEO of Manchester, NH-based Boston Therapeutics (OTCQB: BTHE), writes that Carbohydrates have been shown to play a fundamental role in normal cell functions as well as in major disease pathologies including cancer, cardiovascular disease and inflammatory diseases.
As a class of molecules, carbohydrates have an enormous range of shape, orientation and composition. Due to this structural diversity, carbohydrate chemistry can be applied to develop a broad range of complex therapeutic molecules and drugs, including pure carbohydrates as well as protein-linked carbohydrates, or glycoproteins. However, as a consequence of their structural complexity, carbohydrates have not received as much scientific attention as nucleic acids and proteins. However, significant progress is being made in this area.
Boston Therapeutics is developing a non-systemic, non-toxic chewable complex carbohydrate-based compound named PAZ320 for its ability to lower post-meal elevation of blood glucose, and thus as a treatment to delay or prevent the onset of Type 2 diabetes and related complications such as heart disease, stroke, kidney damage, retinopathy and diabetic foot. The compound is a complex polysaccharide to be taken before meals; it operates in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down carbs in foods during digestion, lowering the amount of available glucose absorbed via the intestine.
Researchers have written a paper, slated to be published in the peer-reviewed journal Endocrine Practice, reporting positive Phase II clinical trial results of PAZ320 in patients with Type 2 diabetes. The study evaluated the combination of PAZ320 and oral agents or insulin in 24 patients with Type 2 diabetes between the ages of 18 and 75 with a body mass index of 25-40 kg/m2 and with HbA1c of less than or equal to nine percent. HbA1c is a lab test that shows the average level of blood sugar (glucose) over the previous three months.
Forty-five percent of patients responded with a 40 percent reduction of post-meal glucose in the blood compared to baseline in a dose-dependent manner. Additionally, results showed the effect of PAZ320 does not correlate with duration of diabetes and works regardless of concurrent diabetes medications. There was no severe hypoglycemia and gastrointestinal side effects were mild. Satiety also was observed. There were no serious adverse events from the data analysis of the open-label dose escalation crossover trial on Type 2 diabetic patients.
In the briefing, Platt explains that a separate potential application of carbohydrate chemistry is as an injectable anti-necrosis drug, both for the prevention of necrosis and the treatment of ischemic conditions that may lead to necrosis. Boston Therapeutics is developing this application under the name IPOXYN. The drug consists of a stabilized glycoprotein composition containing oxygen-rechargeable iron, targeting both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support.
Most Popular Stories
- Boehner Lashes Out Against Ted Cruz, Far Right
- TFA Recruiting DACA Recipients
- Hawaii Official Who Release Obama Certificate Only Victim of Plane Crash
- Holiday Shopping Off to a Slow Start This Season
- Ford Plans New Cars, Jobs in 2014
- Gold, Silver Slide on Prospects of Fed Exit
- 'Rape Insurance' Bill Passes in Michigan
- Ted Cruz Coloring Book Selling Briskly
- Kim Jong Un's Uncle Executed
- Grizzly Bears Could Be Taken Off Endangered List